Gene · 25833
Papers1,618
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
101 to 120 of 1,618
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Unleashing NK cells for cancer immunotherapy in lung cancer: biologic challenges and clinical advances. | J Exp Clin Cancer Res | 2025 | 40849493 | PubTator, text mining | PubMed |
| Current and Emerging Therapeutic Strategies for Limited- and Extensive-Stage Small-Cell Lung Cancer. | Med Sci (Basel) | 2025 | 40843764 | PubTator, text mining | PubMed |
| Characteristic miRNA profiles represent clinicopathological diversity of small cell lung cancer. | J Pathol | 2025 | 40842416 | PubTator, text mining | PubMed |
| Interaction of nanoplastics with metronidazole and ciprofloxacin: The Trojan Horse effect. | PLoS One | 2025 | 40834008 | PubTator, text mining | PubMed |
| Integrated molecular and clinical characterization of pulmonary large cell neuroendocrine carcinoma. | Nat Commun | 2025 | 40830141 | PubTator, text mining | PubMed |
| SLFN11: a pan-cancer biomarker for DNA-targeted drugs sensitivity and therapeutic strategy guidance. | Front Oncol | 2025 | 40766331 | PubTator, text mining | PubMed |
| Redox mechanism of glycerophospholipids and relevant targeted therapy in ferroptosis. | Cell Death Discov | 2025 | 40744916 | PubTator, text mining | PubMed |
| The Cell Ontology in the age of single-cell omics. | ArXiv | 2025 | 40735089 | PubTator, text mining | PubMed |
| Differential expression of haematopoietic prostaglandin D synthase by POU2F3‑positive tuft cells in conventional bilayered oncocytic and metaplastic epithelia of Warthin tumours. | Mol Med Rep | 2025 | 40682850 | PubTator, text mining | PubMed |
| MET and SLFN11 as a Players in the SCLC Molecular Subtyping Game. | Int J Mol Sci | 2025 | 40649874 | PubTator, text mining | PubMed |
| Protein sequence editing defines distinct and overlapping functions of SKN-1A/Nrf1 and SKN-1C/Nrf2. | PLoS Genet | 2025 | 40623109 | PubTator, text mining | PubMed |
| Clinicopathologic, Cellular, and Molecular Analyses of Pulmonary Neuroendocrine Carcinoma With High Expression of Hepatocyte Nuclear Factor 4 Alpha. | Lab Invest | 2025 | 40614900 | PubTator, text mining | PubMed |
| Comprehensive analysis of a real-world cohort identifies geranylgeranyl diphosphate synthase 1 as a predictor of chemoresistance in small cell lung cancer. | Int J Cancer | 2025 | 40613783 | PubTator, text mining | PubMed |
| Immune profiling identifies CD161+CD127+CD8+ T cells as a predictive biomarker for Anti-PD-L1 therapy response in the SCLC-I subtype. | J Transl Med | 2025 | 40597359 | PubTator, text mining | PubMed |
| Prognostic Significance of Immunohistochemical Surrogate Molecular Sub-Typing of Small Cell Lung Carcinoma. | APMIS | 2025 | 40536008 | PubTator, text mining | PubMed |
| Clinical Impact of POU2F3 Expression in Surgically Resected Pulmonary High-Grade Neuroendocrine Carcinoma. | Cureus | 2025 | 40406790 | PubTator, text mining | PubMed |
| Molecular subtyping dictates therapeutic response to anti-PD-L1 immunotherapy in ES-SCLC. | Cancer Immunol Immunother | 2025 | 40402312 | PubTator, text mining | PubMed |
| Molecular heterogeneity of small cell lung cancer and new therapeutic possibilities: a narrative review of the literature. | Transl Lung Cancer Res | 2025 | 40386726 | PubTator, text mining | PubMed |
| Effect of the number of induction chemotherapy cycles on the efficacy of first-line atezolizumab combined with chemotherapy in extensive-stage small cell lung cancer. | Transl Lung Cancer Res | 2025 | 40386714 | PubTator, text mining | PubMed |
| Dissecting small cell carcinoma of the esophagus ecosystem by single-cell transcriptomic analysis. | Mol Cancer | 2025 | 40375239 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/25833/papers?page=6